Literature DB >> 21585398

Antibodies directed against merozoite surface protein-6 are induced by natural exposure to Plasmodium falciparum in a low transmission environment.

S J Jordan1, A L Oliveira, A T Neal, J N Hernandez, O H Branch, J C Rayner.   

Abstract

Malaria caused by Plasmodium falciparum is a major cause of global infant mortality, and there is currently no licensed vaccine that provides protection against infection or disease. Several P. falciparum vaccine targets have undergone early testing, but many more candidates remain with little data to support their development. Plasmodium falciparum Merozoite Surface Protein 6 (PfMSP6) is a candidate of particular interest because it is a member of the PfMSP3 multi-gene family, raising the possibility that vaccine-induced immune responses could cross-react across multiple family members. However, few immunoepidemiological studies of PfMSP6 have been carried out to measure domain-specific anti-PfMSP6 responses. This study investigated anti-PfMSP6 responses in P. falciparum-infected individuals from the Peruvian Amazon, using two different PfMSP6 N-terminal allele antigens and a single C-terminal domain antigen, and compared the responses with both PfMSP6 genotyping data and anti-PfMSP3 response data that had been previously generated for the same samples. Anti-PfMSP6 responses were detected despite the low transmission setting, but were less frequent and of considerably lower intensity than anti-PfMSP3 responses. There was a positive correlation between anti-PfMSP3 and PfMSP6 responses, suggesting that the possibility that PfMSP3 family antigens could induce cross-reactive responses requires further detailed investigation.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21585398      PMCID: PMC4552019          DOI: 10.1111/j.1365-3024.2011.01299.x

Source DB:  PubMed          Journal:  Parasite Immunol        ISSN: 0141-9838            Impact factor:   2.280


  37 in total

1.  Merozoite surface protein 3 and protection against malaria in Aotus nancymai monkeys.

Authors:  Hajime Hisaeda; Allan Saul; Joshua J Reece; Michael C Kennedy; Carole A Long; Louis H Miller; Anthony W Stowers
Journal:  J Infect Dis       Date:  2002-02-14       Impact factor: 5.226

2.  IgG3 antibodies to Plasmodium falciparum merozoite surface protein 2 (MSP2): increasing prevalence with age and association with clinical immunity to malaria.

Authors:  R R Taylor; S J Allen; B M Greenwood; E M Riley
Journal:  Am J Trop Med Hyg       Date:  1998-04       Impact factor: 2.345

3.  Toward the rational design of a malaria vaccine construct using the MSP3 family as an example: contribution of antigenicity studies in humans.

Authors:  Corine G Demanga; Lena-Juliette Daher; Eric Prieur; Catherine Blanc; Jean-Louis Pérignon; Hasnaa Bouharoun-Tayoun; Pierre Druilhe
Journal:  Infect Immun       Date:  2009-11-02       Impact factor: 3.441

4.  Dissection of merozoite surface protein 3, a representative of a family of Plasmodium falciparum surface proteins, reveals an oligomeric and highly elongated molecule.

Authors:  Brandt R Burgess; Peter Schuck; David N Garboczi
Journal:  J Biol Chem       Date:  2005-08-31       Impact factor: 5.157

5.  Identification of a conserved region of Plasmodium falciparum MSP3 targeted by biologically active antibodies to improve vaccine design.

Authors:  Subhash Singh; Soe Soe; Juan-Pedro Mejia; Christian Roussilhon; Michael Theisen; Giampietro Corradin; Pierre Druilhe
Journal:  J Infect Dis       Date:  2004-07-27       Impact factor: 5.226

Review 6.  Do we still need a malaria vaccine?

Authors:  B Greenwood; G Targett
Journal:  Parasite Immunol       Date:  2009-09       Impact factor: 2.280

7.  A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum.

Authors:  Pierre Druilhe; François Spertini; Daw Soesoe; Giampietro Corradin; Pedro Mejia; Subhash Singh; Regine Audran; Ahmed Bouzidi; Claude Oeuvray; Christian Roussilhon
Journal:  PLoS Med       Date:  2005-11-08       Impact factor: 11.069

8.  Malaria vaccines: where next?

Authors:  Anthony A Holder
Journal:  PLoS Pathog       Date:  2009-10-30       Impact factor: 6.823

9.  Naturally acquired antibodies to polymorphic and conserved epitopes of Plasmodium falciparum merozoite surface protein 3.

Authors:  F H A Osier; S D Polley; T Mwangi; B Lowe; D J Conway; K Marsh
Journal:  Parasite Immunol       Date:  2007-08       Impact factor: 2.280

10.  Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3.

Authors:  Christian Roussilhon; Claude Oeuvray; Christine Müller-Graf; Adama Tall; Christophe Rogier; Jean-François Trape; Michael Theisen; Aissatou Balde; Jean-Louis Pérignon; Pierre Druilhe
Journal:  PLoS Med       Date:  2007-11-13       Impact factor: 11.069

View more
  1 in total

1.  Natural antibody response to Plasmodium falciparum merozoite antigens MSP5, MSP9 and EBA175 is associated to clinical protection in the Brazilian Amazon.

Authors:  Márcia M Medeiros; Wesley L Fotoran; Rosimeire C dalla Martha; Tony H Katsuragawa; Luiz Hildebrando Pereira da Silva; Gerhard Wunderlich
Journal:  BMC Infect Dis       Date:  2013-12-28       Impact factor: 3.090

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.